Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
32 Results Found
Toolkit highlights care transitions for patients with OUD or StUD
The AHA released a new toolkit to improve continuity of care for patients with opioid and stimulant use disorders.
SAMHSA releases results from annual survey on drug use and mental health
The Substance Abuse and Mental Health Services Administration July 28 released its latest national survey on drug use and mental health.
House passes SUPPORT Act reauthorization bill
The House June 4 passed the AHA-supported SUPPORT Act (H.R. 2483) by a 366-57 vote.
House committee advances reauthorization of SUPPORT Act
The House Energy and Commerce Committee held a markup April 29 where it advanced the AHA-supported SUPPORT Act (H.R. 2483).
Study finds AI screening for OUD led to fewer hospital readmissions
The National Institutes of Health April 3 released a study that found an artificial intelligence screening tool was as effective as health care providers in identifying hospitalized adults at risk for opioid use disorder and referring them to inpatient addiction specialists.
HHS extends public health emergency for opioid crisis
The Department of Health and Human Services yesterday announced that it renewed the public health emergency for the nation’s opioid crisis an additional 90 days.
Integration of Care: Reducing Barriers to Behavioral Health and Substance Use Disorder Treatment
Mary Thompson, president at Trillium Place and member of AHA’s Committee on Behavioral Health, shares her experience working in the largest mental health and addiction recovery organization in central Illinois.
OIG report finds just 40% of Medicare enrollees who started treatment for opioid use disorder continued
The Department of Health and Human Services Office of Inspector General Feb. 18 released a report that found about 40% of Medicare enrollees who began opioid use disorder treatment with buprenorphine continued with it for at least six months in office-based settings.